Antiplatelet Drugs Market

Antiplatelet Drugs Market [Drug Type: Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIb/IIIa Inhibitors, Adenosine Reuptake Inhibitors, Thromboxane Inhibitors and Phosphodiesterase Inhibitors] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Antiplatelet Drugs Market Outlook 2031

  • The global industry was valued at US$ 2.1 Bn in 2022
  • It is projected to advance at a CAGR of 7.5% from 2023 to 2031 and reach more than US$ 4.1 Bn by the end of 2031

Analysts’ Viewpoint

Increase in prevalence of cardiovascular diseases (CVDs), including heart attack and stroke, is anticipated to augment the demand for antiplatelet drugs and consequently, boost the antiplatelet drugs market growth during the forecast period. Innovation in drug development is further fueling the antiplatelet drugs industry. Rapid growth in geriatric population, unhealthy lifestyles, obesity, and smoking are some of the major factors contributing to the growing incidence of CVDs. This factor is positively impacting the demand for antiplatelet drugs, thus driving market progress.

Additionally, rise in adoption of antiplatelet drugs in emerging economies is creating lucrative growth opportunities for market players. Moreover, various companies in the global market are focusing on innovative strategies, including strategic alliances and acquisitions, to gain revenue benefits.

Antiplatelet Drugs Market

Market Introduction

Antiplatelet drugs are medications that inhibit the ability of platelets to clump together and form blood clots. Platelets play a key role in the blood clotting process, which is essential to prevent excessive bleeding after an injury. However, when platelets clump together inside blood vessels, they can also form blood clots. These can block blood flow to vital organs and lead to serious health issues such as heart attacks and strokes.

Antiplatelet drugs work by interfering with the activity of platelets, reducing their ability to stick together and form clots. There are several types of antiplatelet drugs, including aspirin, ADP receptor inhibitors, phosphodiesterase inhibitors, and glycoprotein IIb/IIIa inhibitors.

Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used as an antiplatelet agent. It works by blocking the action of an enzyme called cyclooxygenase (COX), which is involved in the production of prostaglandins. Aspirin blocking COX and reduces the formation of thromboxane A2, which is a potent platelet activator. ADP receptor inhibitors are a class of antiplatelet drugs that work by blocking the P2Y12 receptor on the surface of platelets.

Phosphodiesterase inhibitors are a class of antiplatelet drugs that work by increasing the concentration of cyclic adenosine monophosphate (cAMP) in platelets. Glycoprotein IIb/IIIa inhibitors are a class of antiplatelet drugs that work by blocking the glycoprotein IIb/IIIa receptor on the surface of platelets.

Growth in Prevalence of Cardiovascular Diseases to Fuel Global Antiplatelet Drugs Market Size

Rise in global prevalence of cardiovascular diseases is a significant factor augmenting the demand for antiplatelet drugs. Cardiovascular diseases, such as heart attacks and strokes, are a leading cause of death worldwide. Rise in geriatric population, unhealthy lifestyles, and smoking habits are the main causes of cardiovascular diseases.

According to the WHO, cardiovascular diseases is the leading cause of death globally. As per estimation, around 17.9 million people died from CVDs in 2019, which represents 32.0% of total deaths, globally. Moreover, 85% of deaths occurred due to strokes and heart attacks.

Antiplatelet drugs play a key role in the prevention and treatment of cardiovascular diseases by reducing the risk of blood clots and subsequent events such as heart attacks and strokes. Therefore, demand for antiplatelet drugs is on the rise.

Innovation in Drug Development Augmenting Market Statistics

Key pharmaceutical manufacturers are engaged in making improvements in existing drugs to increase their efficacy, safety, and patient outcomes. Targeted and efficient drug delivery systems can help ensure that the drug reaches the intended site of action, reducing the risk of side-effects and increasing the effectiveness of the drug. For instance, drug-eluting stents, which slowly release an antiplatelet drug to prevent restenosis and blood clots in patients undergoing angioplasty, are an example of an innovative drug delivery system for antiplatelet drugs.

Development of new antiplatelet drugs is further creating incremental opportunities for market players. For instance, researchers at the University of Illinois Chicago (UIC) have created a novel medication that prevents blood clots without raising the risk of bleeding. Development of novel targets, such as new platelet receptors, or the use of new drug classes, such as monoclonal antibodies is gaining traction. Advances in technology, such as high-throughput screening and molecular modeling, can also aid in the discovery and development of new antiplatelet drugs.

Rise in Adoption of Irreversible Cyclooxygenase (COX) Inhibitors

According to the latest global market analysis, the irreversible cyclooxygenase (COX) inhibitors drug type segment dominated the global market in 2022 and held major antiplatelet drugs industry share.

Irreversible COX inhibitors, also known as aspirin-like drugs, irreversibly inhibit both COX-1 and COX-2 enzymes by acetylating a serine residue in the active site of the enzyme. This irreversible binding results in the permanent inhibition of the enzyme's activity. Aspirin is the most well-known irreversible COX inhibitor and is widely used as an anti-inflammatory and pain reliever. Other irreversible COX inhibitors include indomethacin, diclofenac, and ibuprofen. Increase in adoption of irreversible cyclooxygenase (COX) inhibitors is projected to fuel market expansion in the near future.

Oral Route of Administration of Antiplatelet Drugs Gaining Traction

Based on the route of administration, the global antiplatelet drugs market has been divided into oral and injectable. The oral segment accounted for major share of the global market in 2022. The oral route is the most prescribed route of administration, as it is easy to administer, convenient, and provides a predictable absorption of antiplatelet drugs.

Increase in Usage of Antiplatelet Drugs in Myocardial Infarction and Percutaneous Coronary Intervention

In terms of indication, the antiplatelet drugs market segmentation comprises myocardial infarction, percutaneous coronary intervention, arterial thrombosis, and angioplasty.

Myocardial Infarction (MI), also known as a heart attack, occurs when the blood supply to the heart muscle is blocked, usually by a blood clot, leading to damage to the heart tissue or even death. Percutaneous coronary intervention (PCI) is a minimally invasive procedure used to treat a blocked or narrowed coronary artery in order to restore blood flow to the heart muscle.

PCI is frequently performed in patients suffering from an acute myocardial infarction (AMI), because it can swiftly restore blood supply to the afflicted portion of the heart and avoid additional damage. Antiplatelet therapy is found to be effective for patients undergoing myocardial infarction (MI) or percutaneous coronary intervention (PCI).

Surge in Availability of Antiplatelet Drugs in Hospital Pharmacies

In terms of distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies distribution channel segment accounted for major share in 2022, and it is likely to dominate the global antiplatelet drugs market during the forecast period.

Rise in availability of prescribed oral drugs in hospital pharmacies is a major factor augmenting the segment. This is likely to fuel market value of antiplatelet drugs in the next few years.

Regional Analysis of Global Antiplatelet Drugs Industry

North America accounted for major share of the global market in 2022. The market is likely to maintain its dominance during the forecast period due to the rise in prevalence of chronic diseases in the region. According to the Centers for Disease Control and Prevention (CDC), every six in 10 adults are suffering from chronic diseases. Moreover, chronic diseases including diabetes, cancer, and heart diseases are considered to be the major causes of mortality and disability in the U.S. The antiplatelet drugs market size in North America is likely to increase in the near future, owing to the rise in healthcare expenditure in the region.

The Asia Pacific market is anticipated to expand at a rapid pace in the next few years. Increase in incidence of noncommunicable diseases (NCDs) in the region is contributing to antiplatelet drugs market development.

Analysis of Key Players in Global Antiplatelet Drugs Market

According to the latest antiplatelet drugs market trends, the global industry is fragmented, with the presence of large number of local as well as international players. Market players are gaining lucrative antiplatelet drugs business opportunities by implementing various strategies such as the expansion of product portfolio, mergers, and acquisitions.

Leading players in the global market are Alta Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Pharmaceuticals, Bristol-Myers Squibb Company, F. Hoffmann La Roche, Mylan Pharmaceuticals, Pharmascience, Portola Pharmaceuticals, Sandoz Canada Incorporated, Sanis Health, Shandong Xinhua Pharmaceutical, Syntex, Teva Pharmaceuticals, and The Medicines Company.

Key Developments

  • In June 2021, PhaseBio announced European Licensing Agreement with Alfasigma S.p.A for commercialization of bentracimab. In earlier clinical studies, it was discovered that the new human monoclonal antibody fragment bentracimab could counteract the antiplatelet effects of Brilique/Brilinta.

Key players have been profiled in the antiplatelet drugs market report based on parameters such as company overview, business strategies, business segments, recent developments, financial overview, and product portfolio.

Market Snapshot

Attribute

Detail

Market Size Value in 2022

US$ 2.1 Bn

Market Forecast Value in 2031

US$ 4.1 Bn

Growth Rate

(CAGR)

7.5%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Type
    • Irreversible Cyclooxygenase (COX) Inhibitors
    • Adenosine Diphosphate (ADP) Receptor Inhibitors
    • Glycoprotein IIb/IIIa Inhibitors
    • Adenosine Reuptake Inhibitors
    • Thromboxane Inhibitors and Phosphodiesterase Inhibitors
  • Indication
    • Myocardial Infarction
    • Percutaneous Coronary Intervention
    • Arterial Thrombosis
    • Angioplasty
  • Route of Administration
    • Oral
    • Injectable
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Alta Laboratories
  • AstraZeneca
  • Bayer Pharmaceuticals
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol-Myers Squibb Company
  • F. Hoffmann La Roche
  • Mylan Pharmaceuticals
  • Pharmascience
  • Portola Pharmaceuticals
  • Sandoz Canada Incorporated
  • Sanis Health
  • Shandong Xinhua Pharmaceutical
  • Syntex
  • Teva Pharmaceuticals
  • The Medicines Company

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global antiplatelet drugs market in 2022?

The global market was valued at US$ 2.1 Bn in 2022

How big will antiplatelet drugs industry be in 2031?

It is projected to reach more than US$ 4.1 Bn by 2031

What will be the CAGR of the antiplatelet drugs business during the forecast period (2023–2031)?

The CAGR is likely to be 7.5% from 2023 to 2031

What are the prominent trends that affect industry growth?

Growth in prevalence of cardiovascular diseases and innovation in drug development

Which region is likely to account for major share during the forecast period?

North America is expected to account for major share during the forecast period

Who are the prominent antiplatelet drugs players?

Alta Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb Company, F. Hoffmann La Roche, Mylan Pharmaceuticals, Pharmascience, Portola Pharmaceuticals, Sandoz Canada Incorporated, Sanis Health, Shandong Xinhua Pharmaceutical, Syntex, Teva Pharmaceuticals, and The Medicines Company

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Antiplatelet Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Antiplatelet Drugs Market Analysis and Forecast, 2017-2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Product/Brand Analysis

    5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    5.3. Disease Prevalence & Incidence Rate globally with key countries

    5.4. Pipeline Analysis

6. Global Antiplatelet Drugs Market Analysis and Forecast, by Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Type, 2017-2031

        6.3.1. Irreversible Cyclooxygenase (COX) Inhibitors

        6.3.2. Adenosine Diphosphate (ADP) Receptor Inhibitors

        6.3.3. Glycoprotein IIb/IIIa Inhibitors

        6.3.4. Adenosine Reuptake Inhibitors

        6.3.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors

    6.4. Market Attractiveness, by Drug Type

7. Global Antiplatelet Drugs Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Indication, 2017-2031

        7.3.1. Myocardial Infarction

        7.3.2. Percutaneous Coronary Intervention

        7.3.3. Arterial Thrombosis

        7.3.4. Angioplasty

    7.4. Market Attractiveness, by Indication

8. Global Antiplatelet Drugs Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Route of Administration, 2017-2031

        8.3.1. Oral

        8.3.2. Injectable

    8.4. Market Attractiveness, by Route of Administration

9. Global Antiplatelet Drugs Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2017-2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness, by Distribution Channel

10. Global Antiplatelet Drugs Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness, by Country/Region

11. North America Antiplatelet Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Type, 2017-2031

        11.2.1. Irreversible Cyclooxygenase (COX) Inhibitors

        11.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors

        11.2.3. Glycoprotein IIB/IIIA Inhibitors

        11.2.4. Adenosine Reuptake Inhibitors

        11.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors

    11.3. Market Value Forecast, by Indication, 2017-2031

        11.3.1. Myocardial Infarction

        11.3.2. Percutaneous Coronary Intervention

        11.3.3. Arterial Thrombosis

        11.3.4. Angioplasty

    11.4. Market Value Forecast, by Route of Administration, 2017-2031

        11.4.1. Oral

        11.4.2. Injectable

    11.5. Market Value Forecast, by Distribution Channel, 2017-2031

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. Market Value Forecast, by Country, 2017-2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Drug Type

        11.7.2. By Indication

        11.7.3. By Route of Administration

        11.7.4. By Distribution Channel

        11.7.5. By Country

12. Europe Antiplatelet Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2017-2031

        12.2.1. Irreversible Cyclooxygenase (COX) Inhibitors

        12.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors

        12.2.3. Glycoprotein IIB/IIIA Inhibitors

        12.2.4. Adenosine Reuptake Inhibitors

        12.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors

    12.3. Market Value Forecast, by Indication, 2017-2031

        12.3.1. Myocardial Infarction

        12.3.2. Percutaneous Coronary Intervention

        12.3.3. Arterial Thrombosis

        12.3.4. Angioplasty

    12.4. Market Value Forecast, by Route of Administration, 2017-2031

        12.4.1. Oral

        12.4.2. Injectable

    12.5. Market Value Forecast, by Distribution Channel, 2017-2031

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Drug Type

        12.7.2. By Indication

        12.7.3. By Route of Administration

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. Asia Pacific Antiplatelet Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Type, 2017-2031

        13.2.1. Irreversible Cyclooxygenase (COX) Inhibitors

        13.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors

        13.2.3. Glycoprotein IIB/IIIA Inhibitors

        13.2.4. Adenosine Reuptake Inhibitors

        13.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors

    13.3. Market Value Forecast, by Indication, 2017-2031

        13.3.1. Myocardial Infarction

        13.3.2. Percutaneous Coronary Intervention

        13.3.3. Arterial Thrombosis

        13.3.4. Angioplasty

    13.4. Market Value Forecast, by Route of Administration, 2017-2031

        13.4.1. Oral

        13.4.2. Injectable

    13.5. Market Value Forecast, by Distribution Channel, 2017-2031

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        13.6.1. Japan

        13.6.2. China

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Drug Type

        13.7.2. By Indication

        13.7.3. By Route of Administration

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region

14. Latin America Antiplatelet Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Type, 2017-2031

        14.2.1. Irreversible Cyclooxygenase (COX) Inhibitors

        14.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors

        14.2.3. Glycoprotein IIB/IIIA Inhibitors

        14.2.4. Adenosine Reuptake Inhibitors

        14.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors

    14.3. Market Value Forecast, by Indication, 2017-2031

        14.3.1. Myocardial Infarction

        14.3.2. Percutaneous Coronary Intervention

        14.3.3. Arterial Thrombosis

        14.3.4. Angioplasty

    14.4. Market Value Forecast, by Route of Administration, 2017-2031

        14.4.1. Oral

        14.4.2. Injectable

    14.5. Market Value Forecast, by Distribution Channel, 2017-2031

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Drug Type

        14.7.2. By Indication

        14.7.3. By Route of Administration

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region

15. Middle East & Africa Antiplatelet Drugs Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Drug Type, 2017-2031

        15.2.1. Irreversible Cyclooxygenase (COX) Inhibitors

        15.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors

        15.2.3. Glycoprotein IIB/IIIA Inhibitors

        15.2.4. Adenosine Reuptake Inhibitors

        15.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors

    15.3. Market Value Forecast, by Indication, 2017-2031

        15.3.1. Myocardial Infarction

        15.3.2. Percutaneous Coronary Intervention

        15.3.3. Arterial Thrombosis

        15.3.4. Angioplasty

    15.4. Market Value Forecast, by Route of Administration, 2017-2031

        15.4.1. Oral

        15.4.2. Injectable

    15.5. Market Value Forecast, by Distribution Channel, 2017-2031

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Drug Type

        15.7.2. By Indication

        15.7.3. By Route of Administration

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of companies)

    16.2. Market Share/Ranking Analysis By Company (2022)

    16.3. Company Profiles

        16.3.1. Alta Laboratories

            16.3.1.1. Company Overview

            16.3.1.2. Drug Type Portfolio

            16.3.1.3. SWOT Analysis

            16.3.1.4. Strategic Overview

        16.3.2. AstraZeneca

            16.3.2.1. Company Overview

            16.3.2.2. Drug Type Portfolio

            16.3.2.3. SWOT Analysis

            16.3.2.4. Strategic Overview

        16.3.3. Bayer Pharmaceuticals

            16.3.3.1. Company Overview

            16.3.3.2. Drug Type Portfolio

            16.3.3.3. SWOT Analysis

            16.3.3.4. Strategic Overview

        16.3.4. Boehringer Ingelheim Pharmaceuticals

            16.3.4.1. Company Overview

            16.3.4.2. Drug Type Portfolio

            16.3.4.3. SWOT Analysis

            16.3.4.4. Strategic Overview

        16.3.5. Bristol-Myers Squibb Company

            16.3.5.1. Company Overview

            16.3.5.2. Drug Type Portfolio

            16.3.5.3. SWOT Analysis

            16.3.5.4. Strategic Overview

        16.3.6. F. Hoffmann La Roche

            16.3.6.1. Company Overview

            16.3.6.2. Drug Type Portfolio

            16.3.6.3. SWOT Analysis

            16.3.6.4. Strategic Overview

        16.3.7. Mylan Pharmaceuticals

            16.3.7.1. Company Overview

            16.3.7.2. Drug Type Portfolio

            16.3.7.3. SWOT Analysis

            16.3.7.4. Strategic Overview

        16.3.8. Pharmascience

            16.3.8.1. Company Overview

            16.3.8.2. Drug Type Portfolio

            16.3.8.3. SWOT Analysis

            16.3.8.4. Strategic Overview

        16.3.9. Portola Pharmaceuticals

            16.3.9.1. Company Overview

            16.3.9.2. Drug Type Portfolio

            16.3.9.3. SWOT Analysis

            16.3.9.4. Strategic Overview

        16.3.10. Sandoz Canada Incorporated

            16.3.10.1. Company Overview

            16.3.10.2. Drug Type Portfolio

            16.3.10.3. SWOT Analysis

            16.3.10.4. Strategic Overview

        16.3.11. Sanis Health

            16.3.11.1. Company Overview

            16.3.11.2. Drug Type Portfolio

            16.3.11.3. SWOT Analysis

            16.3.11.4. Strategic Overview

        16.3.12. Shandong Xinhua Pharmaceutical

            16.3.12.1. Company Overview

            16.3.12.2. Drug Type Portfolio

            16.3.12.3. SWOT Analysis

            16.3.12.4. Strategic Overview

        16.3.13. Syntex

            16.3.13.1. Company Overview

            16.3.13.2. Drug Type Portfolio

            16.3.13.3. SWOT Analysis

            16.3.13.4. Strategic Overview

        16.3.14. Teva Pharmaceuticals

            16.3.14.1. Company Overview

            16.3.14.2. Drug Type Portfolio

            16.3.14.3. SWOT Analysis

            16.3.14.4. Strategic Overview

        16.3.15. The Medicines Company

            16.3.15.1. Company Overview

            16.3.15.2. Drug Type Portfolio

            16.3.15.3. SWOT Analysis

            16.3.15.4. Strategic Overview

List of Tables

Table 01: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031

Table 02: Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 03: Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 04: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 05: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031

Table 08: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 09: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 10: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 11: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 12: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031

Table 13: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 14: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 15: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031

Table 18: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 19: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 20: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031

Table 23: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 24: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 25: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 26: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031

Table 28: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

Table 29: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 30: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Antiplatelet Drugs Market Value Share, by Drug Type, 2022

Figure 03: Global Antiplatelet Drugs Market Value Share, by Route of Administration, 2022

Figure 04: Global Antiplatelet Drugs Market Value Share, by Indication, 2022

Figure 05: Global Antiplatelet Drugs Market Value Share, by Distribution Channel, 2022

Figure 06 Global Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 07: Global Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 08: Global Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 09: Global Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 10: Global Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031

Figure 11: Global Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031

Figure 12: Global Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 13: Global Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 14: Global Antiplatelet Drugs Market Value Share Analysis, by Region, 2022 and 2031

Figure 15: Global Antiplatelet Drugs Market Attractiveness Analysis, by Region, 2023-2031

Figure 16: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 17: North America Antiplatelet Drugs Market Value Share Analysis, by Country, 2022 and 2031

Figure 18: North America Antiplatelet Drugs Market Attractiveness Analysis, by Country, 2023-2031 

Figure 19: North America Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 20: North America Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 21: North America Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 22: North America Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 23: North America Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 24: North America Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031

Figure 25: North America Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031

Figure 26: North America Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 27: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 28: Europe Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 29: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 30: Europe Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 31: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 32: Europe Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 33: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 34: Europe Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031

Figure 35: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031

Figure 36: Europe Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 37: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 38: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 39: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 40: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 41: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 42: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 43: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 44: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 45: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031

Figure 46: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031

Figure 47: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 48: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 49: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 50: Latin America Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031

Figure 51: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031

Figure 52: Latin America Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 53: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 54: Latin America Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 55: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 56: Latin America Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031

Figure 57: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031

Figure 58: Latin America Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 59: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 60: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 61: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031

Figure 62: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031

Figure 63: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031

Figure 64: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 65: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

Figure 66: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 67: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031

Figure 68: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031

Figure 69: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 70: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 71: Company Share Analysis, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved